Cool, rereading that interview actually cleared up some things for me too in understanding the two phase 1 trials... That interview and GCs explanation of the different causes of pain really made the need for 2 separate trials more clear. Thanks GC... :)
It also makes more sense why we combined the pain and quality of life with the 2b trials...
"The trial design also includes several secondary endpoints. Among the most important are: (i) the onset of pain and the patient’s need for pain medications; (ii) whether the inoperable tumors become operable as a result of the treatment; (iii) the change in tumor size; and (iv) the patient’s overall quality of life during the treatment".
News 
Market Data 
Discover 
AI
